(S,S) 1-(2-Amino-3,3-dimethyl-butyryl)-2,5-dihydro-1H-pyrrole-2-carbonitrile

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S,S) 1-(2-Amino-3,3-dimethyl-butyryl)-2,5-dihydro-1H-pyrrole-2-carbonitrile
• 英文别名: (2S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-2,5-dihydropyrrole-2-carbonitrile
• 化学式: C₁₁H₁₇N₃O
• 分子量: 207.27
• InChiKey: GYLLRZLSBUCROQ-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (S,S) [1-(2-Cyano-2,5-dihydro-pyrrole-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester 、 三氟乙酸 在 crude product 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以to afford 25 mg of the title compound (1) as the trifluoroacetic acid salt的产率得到(S,S) 1-(2-Amino-3,3-dimethyl-butyryl)-2,5-dihydro-1H-pyrrole-2-carbonitrile
  参考文献：
  名称：

  Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV

  摘要：

  描述了式I的化合物，其中五元环中至少有一条键是双键；B是连接到环上的任何α或β氨基酸，具有酰胺或肽键；或其与药学上可接受的酸或碱的盐。还描述了含有这些化合物的药物组合物。这些化合物可用于治疗II型糖尿病。

  公开号：

  US06645995B2

文献信息

• New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20010031780A1

  公开（公告）日：2001-10-18

  Described are compounds of formula I 1 wherein at least one of the bonds in the five-membered ring is a double bond; B is any alpha or beta amino acid connected to the ring with an amide or peptide bond; or a salt thereof with a pharmaceutically acceptable acid or base. Pharmaceutical compositions containing these compounds are also described. These compounds are useful for treating type II diabetes.

  描述了式I1化合物，其中五元环中至少有一条键是双键；B是任何连接到环上的α或β氨基酸，通过酰胺或肽键；或其与药学上可接受的酸或碱盐。还描述了含有这些化合物的药物组合物。这些化合物对治疗2型糖尿病有用。
• Controlled release composition
  申请人：Nagahara Naoki

  公开号：US20060177509A1

  公开（公告）日：2006-08-10

  The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains 1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate, 2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active ingredient from the release-controlled part B).

  本发明提供了一种控制释放组合物，该组合物显示出活性成分（质子泵抑制剂）在不同的释放速率下控制释放，其中包括1）能够控制活性成分以预定速率释放的释放控制部分A，2）能够控制活性成分以比释放控制部分A更低的预定速率释放的释放控制部分B，必要时还包括3）能够控制活性成分以比释放控制部分B更快的预定速率释放的释放控制部分C，其中活性成分从释放控制部分B的释放先于从释放控制部分A的释放（当包含释放控制部分C时，从释放控制部分C的释放先于从释放控制部分B的释放）。
• Inhibitors of dipeptidyl peptidase iv
  申请人：Belyakov Sergei

  公开号：US20050070719A1

  公开（公告）日：2005-03-31

  Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.

  本发明提供了二肽酶IV（DPP IV）的新型抑制剂，包括含有治疗有效量的DPP IV新型抑制剂的制药组合物，以及新型治疗医学状况的方法。本发明所描述的DPP IV新型抑制剂在治疗神经系统疾病、糖尿病、炎症性疾病如关节炎、肥胖症、骨质疏松症以及其他可用DPP IV抑制剂治疗的疾病方面非常有用。
• SUSTAINED RELEASE PREPARATION
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1537880A1

  公开（公告）日：2005-06-08

  The sustained-release preparation of the present invention, which contains a dipeptidyl peptidase IV inhibitor and a hydrophilic polymer, can appropriately inhibit the DPP-IV activity, and is superior in convenience or compliance.

  本发明的缓释制剂含有二肽基肽酶 IV 抑制剂和亲水性聚合物，可以适当抑制 DPP-IV 的活性，在方便性或顺应性方面更胜一筹。
• CONTROLLED RELEASE COMPOSITION
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1607088A1

  公开（公告）日：2005-12-21

  The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains 1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate, 2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active ingredient from the release-controlled part B).

  本发明提供了一种控释组合物，其活性成分（质子泵抑制剂）的释放可通过两个或多个步骤以不同的释放速率进行控制，该组合物包含 1) 能够控制活性成分以预定速率释放的释放控制部分 A、 2) 能控制活性成分以低于释放控制部分 A 的释放速率的预定速率释放的释放控制部分 B，必要时， 3) 能控制活性成分以快于释放控制部分 B 的释放速率的预定速率释放的释放控制部分 C、其中，活性成分从释放控制部分 B 的释放先于活性成分从释放控制部分 A 的释放（当包含释放控制部分 C 时，活性成分从释放控制部分 C 的释放先于活性成分从释放控制部分 B 的释放）。